Oberweis Asset Management Inc. increased its position in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 21.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 43,229 shares of the biotechnology company’s stock after purchasing an additional 7,642 shares during the quarter. Ligand Pharmaceuticals makes up about 1.3% of Oberweis Asset Management Inc.’s investment portfolio, making the stock its 20th largest holding. Oberweis Asset Management Inc.’s holdings in Ligand Pharmaceuticals were worth $5,866,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Ligand Pharmaceuticals by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,090,137 shares of the biotechnology company’s stock valued at $573,721,000 after purchasing an additional 66,789 shares during the period. Fisher Asset Management LLC increased its position in Ligand Pharmaceuticals by 55.1% during the 4th quarter. Fisher Asset Management LLC now owns 66,105 shares of the biotechnology company’s stock valued at $8,970,000 after buying an additional 23,486 shares in the last quarter. Woodstock Corp increased its position in Ligand Pharmaceuticals by 4.6% during the 4th quarter. Woodstock Corp now owns 69,759 shares of the biotechnology company’s stock valued at $9,466,000 after buying an additional 3,051 shares in the last quarter. Tygh Capital Management Inc. increased its position in Ligand Pharmaceuticals by 108.0% during the 4th quarter. Tygh Capital Management Inc. now owns 80,183 shares of the biotechnology company’s stock valued at $10,881,000 after buying an additional 41,626 shares in the last quarter. Finally, Stevens Capital Management LP bought a new position in Ligand Pharmaceuticals during the 4th quarter valued at approximately $1,336,000.

LGND has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $254.00 price objective on shares of Ligand Pharmaceuticals in a research report on Wednesday. TheStreet lowered Ligand Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Wednesday, January 2nd. Roth Capital reduced their price objective on Ligand Pharmaceuticals from $195.00 to $180.00 and set a “buy” rating for the company in a research report on Thursday, March 7th. ValuEngine lowered Ligand Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 15th. Finally, Zacks Investment Research raised Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, November 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $210.57.

Shares of Ligand Pharmaceuticals stock traded up $0.73 on Friday, reaching $118.93. The company’s stock had a trading volume of 6,804 shares, compared to its average volume of 796,646. The firm has a market cap of $2.42 billion, a price-to-earnings ratio of 18.96, a PEG ratio of 0.18 and a beta of 1.37. Ligand Pharmaceuticals Inc. has a 52 week low of $98.56 and a 52 week high of $278.62. The company has a current ratio of 10.58, a quick ratio of 10.50 and a debt-to-equity ratio of 1.09.

Ligand Pharmaceuticals (NASDAQ:LGND) last posted its earnings results on Thursday, February 7th. The biotechnology company reported $1.70 EPS for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.48. The business had revenue of $59.59 million during the quarter, compared to analyst estimates of $52.58 million. Ligand Pharmaceuticals had a return on equity of 26.00% and a net margin of 57.00%. The company’s quarterly revenue was up 18.1% compared to the same quarter last year. During the same quarter last year, the company earned $1.31 EPS. On average, equities research analysts forecast that Ligand Pharmaceuticals Inc. will post 32.16 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Ligand Pharmaceuticals Inc. (LGND) Shares Bought by Oberweis Asset Management Inc.” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2019/03/15/ligand-pharmaceuticals-inc-lgnd-shares-bought-by-oberweis-asset-management-inc.html.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.

Featured Article: Fiduciary

Want to see what other hedge funds are holding LGND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Inc. (NASDAQ:LGND).

Institutional Ownership by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.